Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Summary
The global Polycystic Kidney Disease Treatment Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019.
Many children with this genetic disorder experience early symptoms of this disease. When both parents carry the disease gene, the risk of developing this condition rises by 25%. However, children with this disease must inherit two defective copies of the gene from their parents. The severity of this condition is usually worse in men, African Americans, and people with sickle cell disease. In most cases, children with this genetic disorder experience kidney failure during their childhood. Diagnosis of polycystic kidney disease is typically simple. It will likely reveal multiple cysts on both kidneys. The kidneys themselves may be normal at the early stages, but later cysts can develop in the liver, spleen, or pancreas.
Drivers
Technological improvements are expected to boost the global polycystic kidney disease treatment market, resulting in the creation of a wide range of medications that will allow physicians to better support polycystic kidney disease patients.
The increasing frequency of chronic renal disease increased R&D for creating novel medications, and specific regulatory approvals are driving the global polycystic kidney disease treatment market. For instance, in May 2022, the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) Application for RGLS8429 (Regulus Therapeutics) to identify its efficacy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients.
Restraints
The worldwide autosomal dominant polycystic kidney disease treatment market is projected to be constrained by underreported autosomal dominant polycystic kidney disease epidemiology and a lack of public knowledge about the condition.
Regional Insights
Due to the surge in prevalence and research on polycystic kidney disease therapy in the United States, as well as favorable health care reimbursement rules, North America is expected to account for a substantial proportion of the global polycystic kidney disease treatment market during the forecast period.
Another important geographic area driving the global polycystic kidney disease treatment market is the Asia Pacific, which is benefiting from the increasing prominence of stem cell therapies and the growing prevalence of genetic disorders.
Competitive Landscape
- Major companies contributing to the global polycystic kidney disease treatment market include Endocyte, Inc., DiscoveryBiomed Inc., Conatus Pharmaceuticals Inc., Madrigal Pharmaceuticals, Inc., Aptevo Therapeutics Inc., Angion Biomedica Corp., Mironid Ltd., Celgene Corp., ManRos Therapeutics, Kadmon Corp LLC, Ipsen SA, and IC-MedTech, Inc.
- In May 2022, the XORTX Therapeutics, Inc., a clinical-stage firm developing treatments for kidney diseases, announced the U.S. FDA had cleared its recent IND application for XRX-OXY-101 treatment.
The Polycystic Kidney Disease Treatment Market report highlights product development and growth strategies such as mergers and acquisitions adopted by market players along with SWOT Analysis, PEST, and Porter’s Five Forces analyses of the Polycystic Kidney Disease Treatment Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.
The Key Manufacturers covered in this Report:-
- Angion Biomedica Corp
- Aptevo Therapeutics Inc
- Celgene Corp
- Conatus Pharmaceuticals Inc
- DiscoveryBiomed Inc
- Endocyte Inc
- IC-MedTech Inc
- Ipsen SA
- Kadmon Corp LLC
- Madrigal Pharmaceuticals Inc.
- ManRos Therapeutics
- Metabolic Solutions Development Company LLC
- Mironid Ltd
By the Product Type, the market is primarily segmented into:
- ANG-3070
- CIM-2
- CR-8
- Others
By Applications, the market is segmented into:
- Clinic
- Research Center
- Hospital
The report covers the following Regions:
- North America
- United States
- Canada
- Mexico
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Central & South America
- Middle East & Africa
- Turkey
- GCC Countries
- Egypt
- South Africa
Objective of the Polycystic Kidney Disease Treatment Market Report:
- To assess the size of the market by value and volume
- Analyze the Polycystic Kidney Disease Treatment Market in terms of regions and major countries
- Highlight recent developments and trends in the market
- Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
- Determine the share of the Polycystic Kidney Disease Treatment Market in terms of various segments such as by product type, application, and end-user
- Offer accurate projection of the market for the forecast period using state–of–the–art tools and the current primary and secondary research approaches
- Discuss major factors that impact the growth of the Polycystic Kidney Disease Treatment Market
The Polycystic Kidney Disease Treatment Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Polycystic Kidney Disease Treatment Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.
For the data information by region, company, type, and application, 2019 are considered the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders:
- Material suppliers/wholesalers
- Market Distributors/traders
- Regulatory bodies
- Research organizations, and consulting firms
- Commercial research & developments (R&D)
- Trade associations and industry bodies
- Importers and exporters
- End-use industries
Available Customizations:
Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into a specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.
